Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
65
Participants
Timeline
Start Date
July 30, 2024
Primary Completion Date
May 30, 2027
Study Completion Date
May 30, 2028
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG
Adebrelimab
adebrelimab, IV
DRUG
albumin paclitaxel
albumin paclitaxel, iv
DRUG
Nedaplatin
Nedaplatin，IV
All Listed Sponsors
lead
Harbin Medical University
OTHER
NCT06508229 - Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC | Biotech Hunter | Biotech Hunter